SEC Filing Document

Company: BIOVENTRIX, INC.
Ticker: 
CIK: 1283259
Filing Type: S-1/A
Document Type: S-1/A
Date Filed: 2026-05-15
Accession Number: 0001493152-26-023752
Exchange: 
SIC Code: 3841
SIC Description: Surgical & Medical Instruments & Apparatus
URL: https://www.sec.gov/Archives/edgar/data/1283259/000149315226023752/forms-1a.htm

Chunk 61 of 94
Word Count: 1407
Character Count: 8706

Document Content:

other stock-based awards, and all other conditions of the other stock-based awards including any dividend and/or voting rights. The Administrator may grant cash awards in such amounts and subject to such performance or other vesting criteria and terms and conditions as the Administrator may determine. Repricing Notwithstanding anything to the contrary in the 2026 Plan, unless a repricing is approved by shareholders, in no case may the Administrator (i) amend an outstanding option or stock appreciation right to reduce the exercise price of the award, (ii) cancel, exchange, or surrender an outstanding option or stock appreciation right in exchange for cash or other awards for the purpose of repricing the award, or (iii) cancel, exchange, or surrender an outstanding option or stock appreciation right in exchange for an option or stock appreciation right with an exercise price that is less than the exercise price of the original award. Equitable Adjustments

the event of a merger, consolidation, recapitalization, stock split, reverse stock split, reorganization, split-up, spin-off, combination,
repurchase or other change in corporate structure affecting the Shares, the Administrator will adjust (i) the number and class of shares
which may be delivered under the 2026 Plan (or number and kind of other securities or other property); (ii) the number, class and price
(including the exercise or strike price of options and stock appreciation rights) of shares subject to outstanding awards, (iii) any
applicable performance criteria, performance period, and other terms and conditions of outstanding performance awards, and (iv) the 2026
Plan’s numerical limits.

Change
in Control

the event of any proposed change in control (as defined in the 2026 Plan), the Administrator will take any action as it deems appropriate,
which action may include, without limitation, the following: (i) the continuation of any award, if we are the surviving corporation;
(ii) the assumption of any award by the surviving corporation or its parent or subsidiary; (iii) the substitution by the surviving corporation
or its parent or subsidiary of equivalent awards; (iv) accelerated vesting of the award, with all performance objectives and other vesting
criteria deemed achieved at targeted levels, and a limited period during which to exercise the award prior to closing of the change in
control, or (v) settlement of any award for the change in control price (less, to the extent applicable, the per share exercise price).
Unless determined otherwise by the Administrator, in the event that the successor corporation refuses to assume or substitute for the
award, a participant shall fully vest in and have the right to exercise the award as to all the underlying Shares, including those that
would not otherwise be vested or exercisable, all applicable restrictions will lapse, and all performance objectives and other vesting
criteria will be deemed achieved at targeted levels.

Term

The
2026 Plan will become effective when approved by our stockholders, and, unless terminated earlier, the 2026 Plan will continue in effect
for a term of ten (10) years.

Amendment
and Termination

Our
Board may amend, alter, suspend, or terminate the 2026 Plan at any time. No amendment or termination of the 2026 Plan will materially
impair the rights of any participant, unless mutually agreed otherwise between the participant and us. Approval of the stockholders shall
be required for any amendment, where required by applicable law, as well as (i) to increase the number of Shares available for issuance
under the 2026 Plan and (ii) to change the persons or class of persons eligible to receive awards under the 2026 Plan.

Recoupment
Policy

All
awards granted under the 2026 Plan, all amounts paid under the 2026 Plan, and all Shares issued under the 2026 Plan shall be subject
to reduction, recoupment, clawback, or recovery by us in accordance with applicable laws and with our policy.

Form

intend to file with the SEC a registration statement on Form S-8 covering the Shares issuable under the 2026 Plan.

Material
United States Federal Income Tax Considerations

The
following is a general summary under current law of the material U.S. federal income tax considerations related to awards and certain
transactions under the 2024 Plan and the 2026 Plan, based upon the current provisions of the Code and regulations promulgated thereunder.
This summary deals with the general federal income tax principles that apply and is provided only for general information. It does not
describe all federal tax consequences under the 2024 Plan and the 2026 Plan, nor does it describe state, local, or foreign income tax
consequences or federal employment tax consequences. The rules governing the tax treatment of such awards are quite technical, so the
following discussion of tax consequences is necessarily general in nature and is not complete. In addition, statutory provisions are
subject to change, as are their interpretations, and their application may vary in individual circumstances. This summary is not intended
as tax advice to participants, who should consult their own tax advisors.

Neither
the 2024 Plan nor the 2026 Plan is qualified under the provisions of Section 401(a) of the Code, and neither is subject to any of the
provisions of the Employee Retirement Income Security Act of 1974, as amended. Our ability to realize the benefit of any tax deductions
described below depends on our generation of taxable income as well as the requirement of reasonableness and the satisfaction of our
tax reporting obligations.

Incentive
Stock Options. No taxable income is generally realized by the optionee upon the grant or exercise of an incentive stock option. If
Shares issued to an optionee pursuant to the exercise of an incentive stock option are sold or transferred after two years from the date
of grant and after one year from the date of exercise, then generally (i) upon sale of such Shares, any amount realized in excess of
the option exercise price (the amount paid for the shares) will be taxed to the optionee as a long-term capital gain, and any loss sustained
will be a long-term capital loss, and (ii) neither we nor our subsidiaries will be entitled to any deduction for federal income tax purposes;
provided that such incentive stock option otherwise meets all of the technical requirements of an incentive stock option. The exercise
of an incentive stock option will give rise to an item of tax preference that may result in alternative minimum tax liability for the
optionee.

the Shares acquired upon the exercise of an incentive stock option are disposed of prior to the expiration of the two-year and one-year
holding periods described above (a “disqualifying disposition”), generally (i) the optionee will realize ordinary income
in the year of disposition in an amount equal to the excess (if any) of the fair market value of the Shares at exercise (or, if less,
the amount realized on a sale of such Shares) over the option exercise price thereof, and (ii) the Company or its subsidiaries will be
entitled to deduct such amount. Special rules will apply where all or a portion of the exercise price of the incentive stock option is
paid by tendering Shares.

an incentive stock option is exercised at a time when it no longer qualifies for the tax treatment described above, the option is treated
as a nonqualified option. Generally, an incentive stock option will not be eligible for the tax treatment described above if it is exercised
more than three months following termination of employment (or one year in the case of termination of employment by reason of disability).
In the case of termination of employment by reason of death, the three-month rule does not apply.

Nonqualified
Options. No income is generally realized by the optionee at the time a nonqualified option is granted. Generally, (i) at exercise,
ordinary income is realized by the optionee in an amount equal to the difference between the option exercise price and the fair market
value of the Shares issued on the date of exercise, and the Company or its subsidiaries receive a tax deduction for the same amount,
and (ii) at disposition, appreciation or depreciation after the date of exercise is treated as either short-term or long-term capital
gain or loss depending on how long the Shares have been held. Special rules will apply where all or a portion of the exercise price of
the nonqualified option is paid by tendering Shares. Upon exercise, the optionee will also be subject to Social Security taxes on the
excess of the fair market value of the Shares over the exercise price of the option.